Calvaruso V, Mazza M, Almasio PL (May 2011). “Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects”. Expert Opin Drug Saf10 (3): 429–35. doi:10.1517/14740338.2011.559161. PMID21323500.
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM (January 2013). “Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C”. N. Engl. J. Med.368 (1): 34–44. doi:10.1056/NEJMoa1208953. PMID23281974.
Berden FA, Kievit W, Baak LC, et al. (October 2014). “Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era”. Neth J Med72 (8): 388–400. PMID25387551.
Tran TT (December 2012). “A review of standard and newer treatment strategies in hepatitis C”. Am J Manag Care18 (14 Suppl): S340–9. PMID23327540.
Calvaruso V, Mazza M, Almasio PL (May 2011). “Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects”. Expert Opin Drug Saf10 (3): 429–35. doi:10.1517/14740338.2011.559161. PMID21323500.
Yau AH, Yoshida EM (September 2014). “Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review”. Can J Gastroenterol Hepatol28 (8): 445–51. PMID25229466.
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM (January 2013). “Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C”. N. Engl. J. Med.368 (1): 34–44. doi:10.1056/NEJMoa1208953. PMID23281974.
